PureLift During Perimenopause and Menopause: The Hormonal-Aging Angle
About the Authors
Bertica M. Rubio, M.D.
Medical Director, Antiaging Regenerative Medicine Clinic | Board-Certified Physician | Dartmouth Medical School
Dr. Bertica M. Rubio is a board-certified physician and Medical Director of the Antiaging Regenerative Medicine Clinic in Redlands, California. She earned her Bachelor of Science degree from Loyola Marymount University and her Doctor of Medicine from Dartmouth Medical School (Geisel School of Medicine). She completed her pediatrics residency at UC Irvine Medical Center.
With decades of clinical experience, Dr. Rubio specializes in age management medicine, regenerative medicine, wound healing, and growth factor therapies. Her practice integrates evidence-based medical science with advanced aesthetic and regenerative treatments, helping patients achieve optimal health and youthful vitality.
Dr. Rubio is passionate about educating patients on the science behind skincare, facial rejuvenation, and non-invasive technologies like EMS (Electrical Muscle Stimulation) for facial toning. Her articles for PureLift LAB combine rigorous medical knowledge with practical guidance for achieving real, lasting results.
Andrew Conrad Barile, PT, DPT
Doctorate of Physical Therapy (DPT), Licensed Physical Therapist (PT)
Dr. Andrew Conrad Barile is a Doctor of Physical Therapy and the CEO and Founder of Xtreem Pulse LLC. He earned his Doctorate in Physical Therapy from Daemen College and brings over two decades of clinical and entrepreneurial experience in pediatric physical therapy, craniosacral therapy, and medical device innovation. His deep understanding of human anatomy, muscle physiology, and therapeutic technology provides invaluable science-backed approach to facial rejuvenation and anti-aging solutions.
Daniel Grinberg, MD, FACS
Board-Certified Otolaryngologist & Head and Neck Surgeon | Fellow, American College of Surgeons | Assistant Clinical Professor, Mount Sinai School of Medicine
Daniel Grinberg, MD, FACS is a Board-Certified Otolaryngologist and Head & Neck Surgeon at ENT and Allergy Associates in West Nyack, NY. He earned his medical degree from Columbia University College of Physicians and Surgeons, completed his Otolaryngology residency at New York University Medical Center, and serves as Assistant Clinical Professor at Mount Sinai School of Medicine. He is a Fellow of both the American College of Surgeons and the American Academy of Otolaryngology.
Dr. Grinberg's head-and-neck surgical perspective brings PureLift LAB readers a wider clinical lens — connecting at-home EMS practice to the underlying medical anatomy with the same scientific rigor we apply to every device specification.
Prof. Dr. med. Ivo Buschmann
Chair of Angiology, Medizinische Hochschule Brandenburg | Clinic Director, University Clinic for Angiology, Brandenburg University Hospital | Former Senior Consultant, Charité Universitätsmedizin Berlin
Prof. Dr. med. Ivo Buschmann is Chair of Angiology at the Medizinische Hochschule Brandenburg Theodor Fontane (MHB) and Clinic Director of the University Clinic for Angiology at the Brandenburg University Hospital. He completed his medical training at the University of Hamburg, served as a Max-Planck Society Fellow at the Max-Planck-Institute for Heart and Lung Research, and held senior consultant positions at the Charité Universitätsmedizin Berlin Campus Virchow before being appointed Chair at MHB in 2016.
Prof. Buschmann is one of Europe's leading authorities on arteriogenesis — the flow-driven growth and remodeling of blood vessels — with more than 150 peer-reviewed publications and several US and EU patents on devices that stimulate collateral blood vessel growth through controlled shear-rate therapy. His research connects mechanical and electrical stimulation to vascular adaptation, microcirculation, and tissue perfusion.
Prof. Buschmann's contributions bring PureLift LAB readers a vascular-biology perspective that complements our existing clinical, physical-therapy, and surgical-anatomy authorship — explaining how EMS stimulation engages not only facial muscles but also the microcirculation that supplies them, and why smart delivery matters at the level of blood flow as much as muscle contraction.
Share
Somewhere between 45 and 55, most women notice that the face they had at 40 isn't quite the face they have now. The jawline softens. The cheek apples deflate slightly. Skin loses some of its bounce. The change is real, it isn't slow, and it has a name: perimenopause, followed by menopause and the postmenopausal years that follow.
The hormonal shift that drives this transition affects almost every system in the body, including the skin and the facial musculature that sits beneath it. This article walks through what is actually happening, why structural facial muscle work matters more during this window than at any other point in adult life, and how to integrate PureLift into a routine that supports the change rather than fighting it.
The short version
- Estrogen decline accelerates skin collagen loss, facial muscle changes, and structural shifts in the SMAS layer.
- The first five years post-menopause see the steepest loss — up to 30% of skin collagen content in some published estimates.
- Facial muscle conditioning has an unusually large effect during this window because the structural problem is muscular and connective, not purely cellular.
- EMS gives you a structural-muscle intervention that topical skincare cannot deliver. It belongs in a perimenopausal and postmenopausal routine.
- The catch: skin is also more reactive during this window. Start at lower intensity. Build slowly.
What changes, hormonally
Perimenopause typically starts in the early-to-mid 40s and runs for 4–10 years before menopause itself (the point of 12 consecutive months without a period). During perimenopause, estrogen and progesterone levels begin to decline and fluctuate. Post-menopause, estrogen settles at a much lower baseline.
The skin and facial musculature responds in several ways:
- Collagen loss accelerates. The most-cited figure in the dermatology literature: up to 30% loss of skin collagen content in the first five years post-menopause, with continued slower loss thereafter.
- Skin thinning. Reduced fibroblast activity means slower production of collagen and elastin. The dermis becomes thinner, less elastic, less able to support the structures above it.
- Hyaluronic acid content drops. Skin loses water-binding capacity. The cheek fullness that depended on hyaluronic acid hydration becomes harder to maintain.
- Facial muscle changes. Sarcopenia — age-related muscle loss — affects facial musculature in addition to skeletal muscle. The zygomaticus major, the masseter, and the platysma can all lose mass with age. Cotofana et al. (2021), publishing in Aesthetic Surgery Journal, documented age-related changes in facial muscle activation patterns using surface electromyography across a 21–82 year age range.
- SMAS laxity. The Superficial Musculo-Aponeurotic System — the fibrous and muscular sheet connecting facial muscle to overlying skin — loses tone, contributing directly to the sagging contour changes characteristic of this stage. Yi & Wan (2025) reviewed this process in detail in the Journal of Cosmetic Dermatology.
None of these changes are reversed by skincare alone. Retinol and vitamin C support the skin layer. Sunscreen prevents further photodamage. But the structural shift — the underlying scaffolding that determines whether your face holds itself up at rest — sits at the muscle and SMAS layer, where topical actives cannot reach.
Why EMS specifically matters in this window
If facial aging in perimenopause and menopause is primarily a structural-scaffolding problem rather than a skin-surface problem, then the interventions that work are interventions that operate at the structural layer. The mainstream interventions:
- Hormone replacement therapy (HRT) — under medical supervision; can address some of the collagen and skin-quality changes but does not directly restore facial muscle tone.
- Injectables — fillers restore volume; neuromodulators reduce specific muscle activity. Effective but expensive, recurring, and not structural in the muscle-conditioning sense.
- Surgical interventions — facelift surgeries directly address SMAS laxity. Highly effective, also highly invasive.
- Facial muscle conditioning — voluntary exercise or assisted electrical stimulation. Builds muscle bulk and tone in the underlying scaffolding.
EMS is the at-home version of structural muscle conditioning. The published clinical evidence on facial NMES specifically — Kavanagh et al. (2012), publishing in the Journal of Cosmetic Dermatology, randomized 108 women aged 32 to 58 to 12 weeks of facial NMES versus no-treatment control. The result was an 18.6% mean increase in zygomaticus major muscle thickness in the NMES group, statistically significant at six and twelve weeks. The age range (32–58) overlaps directly with the perimenopausal years.
Omatsu et al. (2024), in a more recent split-face trial at the University of Tokyo Hospital, found that high-frequency facial NMES at 40–190 kHz produced significant improvements in skin elasticity, jawline angle, submental volume, cheek volume, and nasolabial fold depth in 24 women aged 30 to 59 over 8 weeks of treatment. Again, the age range spans perimenopause and early menopause.
What the clinical trials don't directly answer is whether EMS-induced muscle thickening can offset the rate of menopausal facial aging. They do, however, establish that the underlying mechanism — facial muscle hypertrophy in response to electrical stimulation — is real and measurable in exactly the age cohort this article addresses.
What to expect from PureLift in this window
Three honest framings, based on the clinical evidence and the architecture of how EMS works.
What you can reasonably expect: Measurable improvement in jawline definition, cheek lift, and overall facial firmness over 8–12 weeks of consistent use. A slowing of the rate of structural change. A face that, six months in, sits noticeably differently at rest than it did before starting.
What you should not expect: EMS does not replace estrogen. It does not reverse the underlying hormonal cause of the change. It does not act like a filler — there is no volume restoration in the cellular-replacement sense. The work is muscular, and the visible effect is the structural firmness that strengthened muscle produces.
What it pairs well with: A retinoid-based skincare routine (separated in time, see our EMS + Retinol guide). Sunscreen, every day. Adequate sleep and protein. Hormonal management as advised by your gynecologist, if applicable. If you are on HRT, EMS layers on top of that strategy rather than substituting for it.
The technique adjustments to make at this stage
Skin in perimenopause and menopause is genuinely more reactive than skin in your 30s. A few practical adjustments to the standard PureLift routine:
Start at lower intensity. If you used to run sessions at level 8 in your 30s, start at level 4 or 5 for the first month. Increase gradually as your skin demonstrates tolerance.
Use the Activator Serum every session. Skin barrier function declines in this window. The Activator Serum's water-based conductive layer reduces surface impedance, which means less of the current dissipates as surface tingling and more reaches the muscle layer. Sessions feel smoother and produce more usable muscle engagement.
Three sessions per week is enough. Many users assume that hormonal aging requires more aggressive intervention, so they push to daily sessions. The published dose-response evidence does not support this. Three thoughtful sessions per week, sustained over months, will outperform daily sessions for two weeks followed by burnout.
Pair with sleep and stress management. Cortisol elevation during perimenopause has a measurable effect on facial skin and facial tension. EMS works better when the underlying physiological environment supports it.
Combining with HRT or other interventions
EMS is compatible with hormone replacement therapy. The mechanisms do not interact. HRT addresses the systemic hormonal environment; EMS addresses the local structural musculature. Many of our users on HRT report that their PureLift results visibly improved within 2–3 months of starting hormone therapy, likely because the underlying skin-quality environment shifted in a more responsive direction.
EMS is also compatible with injectables, with timing considerations. Wait at least one week after botulinum toxin injections in the upper face before resuming EMS in the affected areas — running EMS through a recently treated muscle can theoretically affect the neurotoxin's spread, though this is precaution rather than documented contraindication. After hyaluronic acid filler in the cheeks or jawline, wait two weeks before resuming EMS in the filled areas, to allow the filler to integrate without mechanical disturbance.
Consult your aesthetic provider for case-specific timing.
The bottom line
Perimenopause and menopause are real biological events with real structural facial consequences. The interventions that work are the ones that operate at the layer where the structural problem actually lives. EMS belongs in this category — it is not a hormone replacement, it is not a filler substitute, but it is the at-home structural-muscle intervention that complements both. For women in this window, PureLift is one of the highest-leverage non-clinical investments you can make in the face you carry through the next two decades.
For the architectural argument on why facial muscle work matters at all, see The SMAS Layer. For the full published evidence base, see our references hub. For the realistic-timeline question, see Facial EMS Across 12 Months.
If you have specific questions about your perimenopausal or postmenopausal routine — particularly if you are on HRT, considering it, or managing skin conditions like melasma alongside the transition — your gynecologist and dermatologist are the right people to ask. The framework above is the default for healthy adult skin during this window.
References cited: Cotofana S et al. (2021), Aesthetic Surgery Journal 41(9):NP1208-NP1217 (PMID 33942051). Yi K-H, Wan J (2025), Journal of Cosmetic Dermatology 24(12):e70590 (PMID 41413726). Kavanagh S et al. (2012), Journal of Cosmetic Dermatology 11(4):261-266 (PMID 23174048). Omatsu J et al. (2024), Journal of Cosmetic Dermatology 23(10):3222-3233 (PMID 38992992).